![Christopher Kenney](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 386 886 $ am 31.05.2026
Christopher Kenney is currently the Chief Medical Officer at Xenon Pharmaceuticals, Inc. He previously held positions as the Senior Vice President-Medical Affairs at Acorda Therapeutics, Inc. from 2018 to 2019, the Chief Medical Officer at Cadent Therapeutics, Inc. from 2019 to 2020, and the Senior Vice President-Clinical Development at Biotie Therapies LLC from 2013 to 2016.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 07.04.2026 | 7.069 ( 0,01 % ) | 386 886 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Technik-/Wissenschafts-/F&E-Leiter | 23.08.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2020 |
| ACORDA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
Biotie Therapies, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2016 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Acorda Therapeutics, Inc.
 Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies | Health Technology |
Xenon Pharmaceuticals, Inc.
 Xenon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of therapeutics for neurological & psychiatric disorders | Health Technology |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Health Technology |
Biotie Therapies, Inc. |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
